(Total Views: 879)
Posted On: 10/12/2020 8:49:53 PM
Post# of 154409
Re: enemyofpluto #60846
EnemyofPluto,
It is important to remember that monoclonal antibodies are a type of therapy, but that the target and effect of the therapy can be very different. I apologize if I have misunderstood your post, but will continue with my analogy and explanation as best I can.
Explosives can inflate your airbag and save your life or bring down an unneeded building or stadium. Same approach of blowing stuff up, but very different effect.
Lily and Regeneron are using mAbs to replicate antibodies our immune systems would produce to counter the Covid virus (potentially a great step until a good vaccine is available. Replicates the effect of convalescent plasma with greater control than random plasma harvesting). These mAbs supplement the antiviral immune response.
Leronlimab mAb blocks CCR5, stopping immune dysregulation (ARDS, coagulopathy/stroke/heart attack). Similar tool, very different approach to the problem.
Other similar mAbs have failed for targeting single cytokines (tocilizumab targeting Il-6)and not restoring the immune system as a whole by blocking CCR5 and interrupting the inflammatory cascade of monocyte/macrophage trafficking and T cell exhaustion.
I think it appropriate to remember that while leronlimab is an mAb, it nonetheless appears to be in a class by itself.
It is important to remember that monoclonal antibodies are a type of therapy, but that the target and effect of the therapy can be very different. I apologize if I have misunderstood your post, but will continue with my analogy and explanation as best I can.
Explosives can inflate your airbag and save your life or bring down an unneeded building or stadium. Same approach of blowing stuff up, but very different effect.
Lily and Regeneron are using mAbs to replicate antibodies our immune systems would produce to counter the Covid virus (potentially a great step until a good vaccine is available. Replicates the effect of convalescent plasma with greater control than random plasma harvesting). These mAbs supplement the antiviral immune response.
Leronlimab mAb blocks CCR5, stopping immune dysregulation (ARDS, coagulopathy/stroke/heart attack). Similar tool, very different approach to the problem.
Other similar mAbs have failed for targeting single cytokines (tocilizumab targeting Il-6)and not restoring the immune system as a whole by blocking CCR5 and interrupting the inflammatory cascade of monocyte/macrophage trafficking and T cell exhaustion.
I think it appropriate to remember that while leronlimab is an mAb, it nonetheless appears to be in a class by itself.
(12)
(0)
